Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2184-2186, 1997;
This Article
Right arrow Full Text
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ridgway, H. J.
Right arrow Articles by George, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridgway, H. J.
Right arrow Articles by George, P. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 1997;43:2184-2186.)
© 1997 American Association for Clinical Chemistry, Inc.

Technical Briefs

Rapid Detection of the Fibrinogen A{alpha}16Arg->His Mutation

Hayley J. Ridgwaya, Stephen O. Brennan, Andrew P. Fellowes and Peter M. George

a author for correspondence: fax 64-3-364-0545, e-mail hridgway@chmeds.ac.nz

We have now identified mutations in 17 families with dysfibrinogenemias. Over half of these families have the A{alpha}16Arg->His mutation. This mutation is the most commonly reported cause of dysfibrinogenemia and, like other dysfibrinogenemias, is readily detected because of the associated prolonged thrombin and reptilase times (1)(2)(3). The mutation alters the thrombin cleavage site such that release of fibrinopeptide A is delayed. However, fibrinopeptide release assays are difficult and do not directly confirm the molecular basis of the impaired fibrinopeptide release. We have therefore designed a rapid and technically simple PCR-based method for detection of the A{alpha}16Arg->His mutation. This allows reliable identification of a common dysfibrinogenemia that, in its heterozygous form, is usually asymptomatic and does not pose any substantial threat to the health of the patient. Application of this method will allow clinical laboratories to determine the molecular defect in many of the cases that they detect during coagulation studies.

We examined nine families with the A{alpha}16Arg->His mutation. These had been referred for further investigation when routine coagulation studies were consistent with dysfibrinogenemia. All procedures were carried out in accordance with the guidelines of our local ethics committee. Blood samples were collected into Na+ citrate Vacutainer Tubes (Becton Dickinson), and coagulation studies were performed by routine clinical tests for thrombin and . . . [Full Text of this Article]


Acknowledgments


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.